Development Pipeline as at 31 December 2012 Line Extensions Compound Mechanism Area Under Phase Date Estimated Filing Investigation Commenced US EU Japan China Phase Cardiovascular low dose proton pump aspirin inhibitor + associated Axanum III Withdrawn Launched 2016 low dose peptic ulcer in aspirin FDC high risk CV patients outcomes Brilinta/ ADP receptor study in Brilique III 4Q 2012 2016 2016 2016 2017 antagonist patients with EUCLID PAD Brilinta/ outcomes Brilique ADP receptor study in III 4Q 2010 2015 2015 2015 2017 PEGASUS- antagonist patients with TIMI 54 prior MI GLP-1 Bydureon outcomes receptor III 2Q 2010 2018 EXSCEL# study agonist GLP-1 Bydureon Dual receptor diabetes III 3Q 2013 Chamber Pen# agonist Forxiga SGLT2 (dapagliflozin)/ inhibitor + diabetes III 3Q 2007 Filed metformin metformin FDC# FDC diabetes – Forxiga SGLT2 add on to III 1Q 2010 Filed (dapagliflozin)# inhibitor DPP-4 diabetes – add on to Forxiga SGLT2 insulin and III 2Q 2008 Filed (dapagliflozin)# inhibitor add-on to metformin long-term data diabetes – in patients with Forxiga SGLT2 high CV risk - III 1Q 2010 1H 2014 (dapagliflozin)# inhibitor Study 18 and 19 long-term data diabetes – Forxiga SGLT2 triple therapy # III 1Q 2011 1Q 2013 (dapagliflozin) inhibitor (dapa+met+ SU) Kombiglyze DPP-4 XR/ inhibitor + diabetes III Launched Launched 1H 2014 Komboglyze metformin FDC#* FDC DPP-4 SaxaDapa inhibitor / diabetes III 2Q 2012 2015 2015 FDC# SGLT2 inhibitor Onglyza DPP-4 outcomes SAVOR-TIMI III 2Q 2010 4Q 2013 4Q 2013 2H 2014 inhibitor study 53#

Compound Mechanism Area Under Phase Date Estimated Filing Investigation Commenced US EU Japan China Phase Gastrointestinal Crohn’s glucocorticoid disease / Entocort III Launched Launched 2015 steroid ulcerative colitis proton pump peptic ulcer Nexium III Filed** Launched N/A Launched inhibitor bleeding Neuroscience sedative and conscious Diprivan# III Launched 1H 2014 Launched anaesthetic sedation Oncology oestrogen 1st line Faslodex receptor advanced III 4Q 2012 2016 2016 2016 2016 antagonist breast cancer EGFR treatment tyrosine Iressa beyond III 1Q 2012 2015 2015 2015 kinase progression inhibitor Respiratory & Inflammation Breath inhaled Actuated steroid/ long- Symbicort*** Inhaler III 4Q 2011 1H 2014 acting β 2 asthma / agonist COPD

#Partnered product *Kombiglyze XR US; Komboglyze FDC EU **2nd CRL received from FDA in 2011. AZ response submitted to FDA in December 2012 ***Excludes Symbicort pMDI post marketing LABA safety study

NCEs Phase III/Registration

Compound Mechanism Area Under Phase Date Estimated Filing Investigation Commenced US EU Japan China Phase Cardiovascular ADP receptor arterial Brilinta/Brilique III Launched Launched 2Q 2013 Approved antagonist thrombosis Forxiga SGLT2 diabetes III Filed* Launched 2Q 2013 1Q 2013 (dapagliflozin)# inhibitor # leptin metreleptin lipodystrophy III 2Q 2013 N/A analogue Infection beta CAZ AVI# lactamase serious III 1Q 2012 N/A 2H 2014 2H 2014 2016 (CAZ104) inhibitor/ infections cephalosporin live, attenuated, Q-LAIV intranasal seasonal Flu III Approved Filed influenza influenza Vaccination** virus vaccine (quadrivalent) extended spectrum # Zinforo cephalosporin / (ceftaroline) with affinity to III N/A Launched 1H 2014 skin infections penicillin- binding proteins Neuroscience oral peripherally- opioid- naloxegol acting mu- # induced III 2Q 2011 3Q 2013 3Q 2013 (NKTR-118) opioid constipation receptor antagonist Oncology VEGFR / EGFR tyrosine Caprelsa medullary kinase III Launched Launched 2015 Filed thyroid cancer inhibitor with RET kinase activity Respiratory & Inflammation anti-IL-17R # psoriasis III 3Q 2012 2015 2015 MAb spleen tyrosine rheumatoid fostamatinib# III 3Q 2010 4Q 2013 4Q 2013 kinase (SYK) arthritis inhibitor chronic management selective of lesinurad inhibitor of III 4Q 2011 1H 2014 1H 2014 2017 2017 hyperuricaemia URAT1 in patients with gout

#Partnered product *CRL received in January 2012 **sBLA in US, MAA in EU

NCEs Phases I and II

Compound Mechanism Area Under Phase Date Estimated Filing Investigation Commenced US EU Japan China Phase Cardiovascular end stage renal disease NHE3 AZD1722# / chronic I 4Q 2010 inhibitor kidney disorder Gastrointestinal anti-IL-13 ulcerative II 2Q 2012 MAb colitis Infection oxazolidinone AZD5847 anti-bacterial tuberculosis II 4Q 2012 inhibitor beta # lactamase CXL MRSA II 4Q 2010 inhibitor/ cephalosporin targeted serious ATM AVI BL/BLI I 4Q 2012 bacterial infections pandemic pandemic MEDI-550 influenza influenza I 2Q 2006 virus vaccine prophylaxis RSV anti-RSV prevention in MAb – high risk MEDI-557 I 3Q 2007 extended adults half-life (COPD/CHF/ other) paediatric RSV MEDI-559 I 4Q 2008 RSV vaccine prophylaxis Neuroscience myeloper- oxidase Parkinson’s AZD3241 II 2Q 2012 (MPO) disease inhibitor alpha4/beta2 neuronal Alzheimer’s AZD3480# nicotinic II 3Q 2007 disease receptor agonist histamine-3 Alzheimer’s AZD5213 receptor II 2Q 2012 disease antagonist NMDA major AZD6765 receptor depressive II 3Q 2007 antagonist disorder alpha4/beta2 neuronal Alzheimer’s AZD1446# nicotinic I 4Q 2008 disease receptor agonist # beta Alzheimer’s AZD3293 I 4Q 2012 secretase disease rheumatoid MEDI5117 anti-IL-6 MAb I 2Q 2012 arthritis

#Partnered product

NCEs Phases I and II (continued)

Compound Mechanism Area Under Phase Date Estimated Filing Investigation Commenced US EU Japan China Phase Oncology FGFR tyrosine AZD4547 solid tumours II 4Q 2011 kinase inhibitor spleen tyrosine haematological fostamatinib# II 1Q 2012 kinase (SYK) malignancies inhibitor anti-CD19 haematological MEDI-551# II 1Q 2012 MAb malignancies MEDI-573# anti-IGF MAb MBC II 4Q 2011 anti-PDGFR- MEDI-575# NSCLC II 2Q 2011 alpha MAb gBRCAm ovarian PARP cancer, olaparib II 1Q 2012 inhibitor gBRCAm breast cancer, gastric cancer selumetinib# (AZD6244) MEK inhibitor solid tumours II 4Q 2006 (ARRY- 142886) anti-CTLA4 solid tumours II 3Q 2004 MAb PIM kinase haematological AZD1208 I 1Q 2012 inhibitor malignancies TOR kinase AZD2014 solid tumours I 1Q 2010 inhibitor AZD5363# AKT inhibitor solid tumours I 4Q 2010 AZD8330# (ARRY MEK inhibitor solid tumours I 1Q 2007 424704) STAT3 haematological AZD9150 I 1Q 2012 inhibitor malignancies anti-DLL-4 MEDI0639# solid tumours I 2Q 2012 MAb anti-ANG-2 MEDI3617# solid tumours I 4Q 2010 MAb anti-PD-L1 MEDI4736# solid tumours I 3Q 2012 MAb anti-CEA MEDI-565# solid tumours I 1Q 2011 BiTE murine anti- MEDI6469# solid tumours I 1Q 2006 OX40 MAb moxetumomab anti-CD22 haematological pasudotox# recombinant I 2Q 2007 malignancies immunotoxin volitinib# MET inhibitor solid tumours I 1Q 2012

#Partnered product

NCEs Phases I and II (continued)

Compound Mechanism Area Under Phase Date Estimated Filing Investigation Commenced US EU Japan China Phase Respiratory & Inflammation AZD2115# MABA COPD II 2Q 2012

AZD5069 CXCR2 asthma II 4Q 2010 inhaled AZD5423# COPD II 4Q 2010 SGRM anti-IL-5R # asthma / COPD II 4Q 2008 MAb anti-GM- rheumatoid # II 1Q 2010 CSFR MAb arthritis anti-IFN- MEDI-546# SLE II 1Q 2012 alphaR MAb Crohn’s disease anti-a4b7 MEDI7183# / ulcerative II 4Q 2012 MAb colitis anti-IL-1R MEDI8968# COPD II 4Q 2011 MAb anti-IFN- # SLE II 3Q 2008 alpha MAb anti-IL-13 tralokinumab asthma / IPF II 1Q 2008 MAb AZD8848# inhaled TLR7 asthma I 2Q 2012 inhaled AZD7594# COPD I 4Q 2012 SGRM # anti-IL-23 MEDI2070 Crohn’s disease I 2Q 2010 MAb MEDI4212 anti-IgE MAb asthma I 1Q 2012 anti-CD19 multiple MEDI-551# I 3Q 2012 MAb sclerosis # anti-B7RP1 MEDI5872 SLE I 4Q 2008 MAb anti-C5/C5a MEDI7814 COPD I 1Q 2012 MAb anti-TSLP MEDI9929# asthma I 4Q 2008 MAb chronic selective management of RDEA3170 inhibitor of hyperuricaemia I 3Q 2011 URAT1 in patients with gout

#Partnered product

Completed Projects

Compound Mechanism Area Under Phase Date Estimated Filing Investigation Commenced US EU Japan China Phase Cardiovascular outcomes in Crestor# statin subjects with Launched Launched Launched elevated CRP Gastrointestinal proton pump Nexium GERD Launched Launched Launched Launched inhibitor Infection live, attenuated, FluMist/Fluenz intranasal influenza Launched Launched

influenza virus vaccine Neuroscience local topical EMLA Launched Launched anaesthetic anaesthesia Oncology EGFR tyrosine 1st line EGFR Iressa Launched Launched Launched kinase mut+ NSCLC inhibitor High dose oestrogen nd (500mg) 2 Faslodex receptor Launched Launched Launched line advanced agonist breast cancer Bone disorders Ranmark# anti-RANKL stemming Launched () MAb from bone metastasis Respiratory & Inflammation long-acting β Oxis 2 COPD Launched Launched Launched agonist inhaled steroid/ long- Symbicort COPD Launched Launched Launched Launched acting β2 agonist inhaled steroid/long Symbicort SMART Launched Launched Launched acting β2 agonist

Development Pipeline - Discontinued Projects between 30 June 2012 and 31 December 2012

Cardiovascular NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation NCE AZD2820 Safety/Efficacy obesity NCE AZD4017 Safety/Efficacy glaucoma

Infection NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation NCE AZD9773 Safety/Efficacy severe sepsis

Oncology NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation NCE AZD1480 Safety/Efficacy solid tumours NCE AZD3514 Safety/Efficacy prostate cancer breast cancer chemo. NCE AZD8931 Safety/Efficacy combi./solid tumours selumetinib (AZD6244) NCE Study completed solid tumours (ARRY-142886)/MK2206#

Respiratory & Inflammation NCE/Line Extension Compound Reason for Area Under Investigation Discontinuation NCE AZD8683 Safety/Efficacy COPD NCE MEDI-570 Safety/Efficacy SLE

Comments As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Submission dates shown for assets in Phase III and beyond.